Albain et al. examined the effect of ACT containing cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) in a randomized phase III trial on 1477 postmenopausal women with hormone-receptor-positive, node-positive BC on disease-free survival (DFS) [20]. This evidence concerns the gene NR4A1 and breast cancer.